Lumos Pharma

Lumos Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases, with a strategy grounded in time- and cost-efficient drug development. Its lead program is LUM-201, an oral growth hormone stimulating agent in clinical development for Pediatric Growth Hormone Deficiency (PGHD) — a condition causing growth retardation and short stature. If approved by the FDA, LUM-201 would offer an oral alternative to the daily injections that PGHD patients currently endure for years of treatment. Phase 2 trials (OraGrowtH210 and OraGrowtH212) met all primary and secondary endpoints. Beyond PGHD, Lumos Pharma actively seeks strategic partnerships to expand its rare disease pipeline through licensing or acquisition of novel therapeutic candidates, leveraging expertise spanning endocrinology, neurology, and inborn errors of metabolism.